Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenylethynesulfonamide (PES), also known as pifithrin-mu (PFT-mu), is a small molecule inhibitor of the heat shock protein 70 (HSP70) family, including the constitutively expressed HSC70. It interacts specifically with the C-terminal substrate-binding domain (SBD) of HSP70, disrupting its chaperone activity and interaction with co-chaperones. This interference leads to the aggregation of misfolded proteins, inhibition of autophagy, and destabilization of the HSP90-mediated protein folding machinery, which in turn reduces the levels of oncogenic client proteins such as HER2, AKT, and CDK4. PES has also been shown to inhibit the Anaphase Promoting Complex/Cyclosome (APC/C), inducing G2/M cell cycle arrest. It exhibits selective cytotoxicity toward cancer cells, particularly in models of melanoma and B-cell lymphoma, while sparing normal cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenylethynesulfonamide.